Did you know?
ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.
Free Newsletter
Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!
Free Report
Sinovac Raises $515 Million to Double COVID-19 Vaccine Production
In July, Sinovac started the Phase III trial for CoronaVac in
SinoBiopharm manufactures TCM and western chemical drugs through a large number of subsidiaries.
Control of Sinovac has been a matter of long-term dispute between existing management, which wants to take the company private, and an investor group which wants control of the company and would also take the company private. It has not traded on the NASDAQ exchange for over a year and a half.
“We have made significant progress in the development of our COVID-19 vaccine candidate CoronaVac, which has reached critical milestones in clinical trials in Asia and
Sinovac's product portfolio includes vaccines for:
- enterovirus71 (EV71),
• hepatitis A and B, s
• seasonal influenza,
• H5N1 pandemic influenza (avian flu),
• H1N1 influenza (swine flu),
• varicella vaccine and
• mumps.
The company is developing a number of new products including
- a Sabin-strain inactivated polio vaccine,
• pneumococcal polysaccharides vaccine,
• a quadrivalent influenza vaccine and
• a SARS-CoV-2 (commonly referred to as COVID-19) vaccine.
See our other articles on Sinovac.
Disclosure: none.
ChinaBio® News
Greg Scott Interviewed at BIO-Europe Spring
How to bring your China assets to China in 8 minutes
"Mr. Bio in China."
Mendelspod Interview
Multinational pharma held to a higher standard in China